Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really? How did you do that when it is suspended?
Again, thanks much. Will check out.
Thanks for the info. My "free" cleaner was from reimagerepair. I don't think it is malware but just a scam to get one to pay for a sub at the end.
Anyone here using a true FREE "cleaner for slow computer" app? I downloaded what was supposed to be "free" REIMAGEREPAIR from pccleaner.com which was a scam. It was FREE to download then after "cleaning" my puter wanted $$ to "fix it".
Jail it should be. What about a lawsuit?
Thanks for clearing up massive misinformation. It’s good to see those with good drug knowledge undertaking that task here.
So, how many shares have traded in the “premarket”?
Really? I thought the brick wall was .08 only a few days ago.
running out of gas - watch for a quick stop down to .17
IPIX up 55% on Covid-19 news
I think a lot of people just have been given information to ease their minds (placate then), they maybe find it too frightening to really take it in completely and it is too far from any real life experiences prior, and they just can’t get their noodle around it and what it means for them. I understand. But the problem is that people who tried to tell them, were denounced as fear mongerers. The best time to have stopped this was when it was still early and fairly inconceivable. But that’s when resistance to doing anything is also highest.
Good luck and stay safe and well!
Also, Bayer donated three million doses over a week ago.
How about this country-Chinese authorities lied about the pandemic by minimizing the threat, punishing those of its people who spoke the truth, deliberately concealing information, and delayed public announcements, which denied the World Health Organization a timely investigation.
When PR drops, see ya .025 plus with this tiny retail float.
Any comment on the PR from SEC?
It was obvious when the illegal manipulating scammer crew moved in, en mass, who I reported to the SEC.
Coronovirus stocks to watch:
https://insiderfinancial.com/coronavirus-secondary-stocks-to-watch/179746/
Test kits, masks, telehealth Covid-19 plays.
https://insiderfinancial.com/coronavirus-secondary-stocks-to-watch/179746/
So, when did the trials stop? If so, please provide a link.
Back up your "expert" advice by going out and hugging a COVID victim. Prove it by posting a photo. Thanks.
Thanks much.
A month or so ago I posted this on the Computer Help thread:
Any help here will be appreciated. The following scam shows up only on my iPad and on the IHub site. While on investorshub a popup scam "you have been picked for a $1000 prize" website luckyguys.top/prize/luckyus-ad hijacks my iPad screen. Trying to leave that site is impossible and another scam site 7year.co appears. I have to completely leave IHub then when I return the same scam appears. My PC doesn't have this problem perhaps because it runs on Windows 10 and I have Avast antivirus. Can I fix this by getting Avast or another antivirus on iPad?
Two weeks ago this scam ad appeared when I was on the PXYN board along with a couple more scam ads and I could not click out of them. It lasted for 2-3 days then disappeared only to reappear yesterday and again I cannot click out of it. The ad is from"COX Cable offering gift cards from WM, Amazon,etc". The link in my header showed "Not Secure"-VIP.fortunatetime.XYZ
Another poster on the Computer board posted yesterday he had the same problem.Thanks.
Your school not holding classes today? If not it’s a good time to catch up on Covid-19 news.
Does your school allow you to post during classroom hours?
Link please.
Will do.
Nope, SEC.gov is legitimate. So is the FBI because I forwarded your "article" to both of them for investigation.
Scamming con artistes should not only be reported to the SEC but FBI also.
Forwarded this tin the SEC to see if it’s true.
Forwarded this to SEC for a double check.
Really? I thought the brick wall was .08 yesterday or day before.
Just how many times can a three-line sentence or thought process be "reconstructed" to say the same thing? I've been in this stock for 3-4 years but just don't have the time to read every post.
ad nau·se·am
/ad 'nôze?m/
adverb
referring to something that has been done or repeated so often that it has become annoying or tiresome.
My thanks to several knowledgeable posters here though.
IPIX breaking out on Coronavirus PR
Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment
7:00 am ET March 2, 2020 (Globe Newswire) Print
March 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, is pleased to provide scientific rationale and clinical development perspectives for Brilacidin, the Company's defensin mimetic drug candidate, as a potential novel coronavirus (COVID-19) treatment. Notably, Brilacidin is one of the few drugs targeting COVID-19 that has been tested in humans in Phase 2 clinical trials for other clinical indications, providing an established safety and efficacy profile, thereby potentially enabling it to rapidly help confront the emerging worldwide coronavirus crisis.
Linked below is an overview document (a downloadable pdf) summarizing the scientific rationale for developing Brilacidin as a potential COVID-19 treatment, both as an intravenous medication and as a possible vaccine.
"Background and Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment" (March 1, 2020)
http://www.ipharminc.com/s/IPIX-Brilacidin-Defensin-Mimetics-COVID-19-Overview-March-1-2020-update.pdf
Defensins are small antimicrobial peptides expressed widely in the animal kingdom that serve as the first line of defense against foreign invasion of the body.
Defensin-based therapeutics--of which Brilacidin is the leading example, and the most advanced drug candidate among this class currently in clinical testing--represent an attractive possible intervention to combat the coronavirus given innate and multifaceted immunomodulatory properties. Defensins exhibit a number of distinct and highly favorable therapeutic characteristics: anti-bacterial, anti-inflammatory, anti-fungal, anti-biofilm, anti-cancer, and antiviral.
Brilacidin, a mimetic of defensins, was computationally designed to be smaller (1/10th the size), more stable, more potent (by a 100-fold) and more selective (by a 1000-fold) than natural defensins, a type of antimicrobial peptide, so as to overcome most shortcomings (e.g., degradation, toxicity, malabsorption, high-cost of manufacturing) that have complicated their clinical development. The antiviral properties of natural defensins and their synthetic mimics are actively being studied by virologists the world over, with newer understandings elucidating their direct mechanisms of action against non-enveloped and enveloped viruses alike, along with their role in the regulation of inflammation and chemoattraction.
As disclosed, the Company is shipping Brilacidin drug substance this week to a U.S.-based Regional Biocontainment Lab (RBL) to evaluate its potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the virus responsible for COVID-19. It is anticipated that these tests might be completed within several weeks of the RBL's receipt of Brilacidin. Separately, a Material Transfer Agreement (MTA), with a leading University Virology Lab overseen by one the world's top coronavirus experts, is anticipated to be executed this week. The Company has also submitted a preliminary summary of Brilacidin's potential as a novel coronavirus treatment to the U.S. Government's Biomedical Advanced Research and Development Authority (BARDA), dedicated to rapidly identifying and funding medical countermeasures to COVID-19. There is no assurance made or implied that testing of Brilacidin for any coronavirus will be successful.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the future execution of a definitive agreement with a global pharmaceutical company and the anticipated terms thereof, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
__GNW8366DE3E__IMG
Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment
7:00 am ET March 2, 2020 (Globe Newswire) Print
March 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, is pleased to provide scientific rationale and clinical development perspectives for Brilacidin, the Company's defensin mimetic drug candidate, as a potential novel coronavirus (COVID-19) treatment. Notably, Brilacidin is one of the few drugs targeting COVID-19 that has been tested in humans in Phase 2 clinical trials for other clinical indications, providing an established safety and efficacy profile, thereby potentially enabling it to rapidly help confront the emerging worldwide coronavirus crisis.
Linked below is an overview document (a downloadable pdf) summarizing the scientific rationale for developing Brilacidin as a potential COVID-19 treatment, both as an intravenous medication and as a possible vaccine.
"Background and Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment" (March 1, 2020)
http://www.ipharminc.com/s/IPIX-Brilacidin-Defensin-Mimetics-COVID-19-Overview-March-1-2020-update.pdf
Defensins are small antimicrobial peptides expressed widely in the animal kingdom that serve as the first line of defense against foreign invasion of the body.
Defensin-based therapeutics--of which Brilacidin is the leading example, and the most advanced drug candidate among this class currently in clinical testing--represent an attractive possible intervention to combat the coronavirus given innate and multifaceted immunomodulatory properties. Defensins exhibit a number of distinct and highly favorable therapeutic characteristics: anti-bacterial, anti-inflammatory, anti-fungal, anti-biofilm, anti-cancer, and antiviral.
Brilacidin, a mimetic of defensins, was computationally designed to be smaller (1/10th the size), more stable, more potent (by a 100-fold) and more selective (by a 1000-fold) than natural defensins, a type of antimicrobial peptide, so as to overcome most shortcomings (e.g., degradation, toxicity, malabsorption, high-cost of manufacturing) that have complicated their clinical development. The antiviral properties of natural defensins and their synthetic mimics are actively being studied by virologists the world over, with newer understandings elucidating their direct mechanisms of action against non-enveloped and enveloped viruses alike, along with their role in the regulation of inflammation and chemoattraction.
As disclosed, the Company is shipping Brilacidin drug substance this week to a U.S.-based Regional Biocontainment Lab (RBL) to evaluate its potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the virus responsible for COVID-19. It is anticipated that these tests might be completed within several weeks of the RBL's receipt of Brilacidin. Separately, a Material Transfer Agreement (MTA), with a leading University Virology Lab overseen by one the world's top coronavirus experts, is anticipated to be executed this week. The Company has also submitted a preliminary summary of Brilacidin's potential as a novel coronavirus treatment to the U.S. Government's Biomedical Advanced Research and Development Authority (BARDA), dedicated to rapidly identifying and funding medical countermeasures to COVID-19. There is no assurance made or implied that testing of Brilacidin for any coronavirus will be successful.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the future execution of a definitive agreement with a global pharmaceutical company and the anticipated terms thereof, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
__GNW8366DE3E__IMG
Well , after all, our self-proclaimed “Great Genius” President who told us he knows more than the Generals, Intel experts, Scientists, etc, just told us that the U.S. had a very “low chance” of a nationwide Covid-19 outbreak. This after the CDC and NIH said It’s not a matter of “if” but when.
Now, do we believe our learned scientists or our pseudo-“scientist”? I’m a lifetime Republican and will go with the real medical experts , not a narcissistic know it all.
I’ve already stocked up on masks, eyeglasses, etc.
Only a handful, but I enjoy exposing scammers and keep my hopes alive they will look at this gang.
I didn’t allow the criminal con-artists scare me today. Instead, I purchased more at $13.10. I did send note to SEC suggesting an investigation of the criminal manipulators.
POSSIBLE CORONAVIRUS DRUGS IN CLINICAL TRIALS
https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
$3.00? I’m still waiting for $2.20 to double my holdings.
Any chance of this being a $15 Billion performer ?
"MXAMDUD Thursday, 02/13/20 11:57:33 AM
Re: None 0
Post #
281780
of 281848
I have been told by a friend that treatment for his colonic disease requires a 4 hour clinic visit with an IV and the EOB report indicates about $1K for the treatment every 8 weeks or so. He indicates that taking a pill with so many side effects would be of limited benefit for many This seems like the type of news that would have BPs indifferent to get involved with the B franchise considering the limited market. I hear some of the ongoing backroom discussions and especially LW is disappointed in today's results."
Where did "your friend" hear of "so many side effects"? Why don't you invite "your friend" to post his concerns himself here on the board?
Where did you "hear" about the "backroom discussions"?